Table 2.
ECMO weaning rate, neurological outcome, and hemodynamic data.
| ECPELLA (30) | VA-ECMO (30) | p-value | |
|---|---|---|---|
| VA-ECMO weaning | 19 (63) | 8 (27) | < 0.01 |
| Favorable neurological outcome* | 10 (33) | 2 (7) | < 0.01 |
| 30-day survival | 16 (53) | 6 (20) | < 0.01 |
| Hemodynamic Data | |||
| D1-heart rate, bpm | 76 ± 22 | 79 ± 23 | 0.59 |
| D2-heart rate, bpm | 66 ± 20 | 78 ± 28 | < 0.01 |
| D3-heart rate, bpm | 68 ± 22 | 83 ± 29 | 0.09 |
| D1-MAP, mmHg | 75 ± 15 | 60 ± 20 | < 0.01 |
| D2-MAP, mmHg | 72 ± 17 | 69 ± 25 | 0.63 |
| D3-MAP, mmHg | 67 ± 14 | 59 ± 16 | 0.08 |
| D1-Arterial pulse pressure, mmHg | 11 [8–33] | 34 [19–55] | < 0.01 |
| D2-Arterial pulse pressure, mmHg | 13 [4.5–34] | 43 [20–72] | < 0.01 |
| D3-Arterial pulse pressure, mmHg | 17.5 [6–36] | 40 [23–68] | < 0.01 |
| D1-mPAP, mmHg | 16 ± 5 | 18 ± 9 | 0.29 |
| D2-mPAP, mmHg | 20 ± 7 | 21 ± 11 | 0.75 |
| D3-mPAP, mmHg | 17 ± 5 | 20 ± 7 | 0.21 |
| D1-PAPI | 1.3 [1.1–3.6] | 3.8 [2.1–6.0] | < 0.01 |
| D2-PAPI | 4.3 [0–11.2] | 3.1 [0–10.1] | 0.96 |
| D3-PAPI | 5.0 [0–10.3] | 5.9 [0–17.3] | 0.36 |
| D1-CVP, mmHg | 9.5 ± 4.8 | 11.4 ± 6.8 | 0.29 |
| D2-CVP, mmHg | 11.2 ± 3.7 | 13.5 ± 7.1 | 0.18 |
| D3-CVP, mmHg | 9.4 ± 3.7 | 14.3 ± 6.4 | < 0.05 |
| D1-Vasoactive-inotrope score | 4.3 [0–11.2] | 3.1 [0–10.1] | 0.96 |
| D2-Vasoactive-inotrope score | 5.0 [0–10.3] | 5.9 [0–17.3] | 0.36 |
| D3-Vasoactive-inotrope score | 1.0 [0–7.8] | 11.1 [0–18.7] | 0.07 |
Data were expressed as n (%), mean ± standard deviation or median [inter-quartile range]. Statistical significance was defined as p < 0.05. CVP: central venous pressure, D1, D2, D3 are, respectively, mechanical circulatory support day 1, day 2, and day 3. ECMO: extracorporeal membrane oxygenation, ECPELLA: venoarterial-ECMO + Impella, MAP: mean arterial pressure, OHCA: out-of-hospital cardiac arrest, PAPI: pulmonary artery pulsatile index.
*
defined as cerebral performance category (CPC) scales at 1 or 2 at the timing of hospital discharge.